
Quarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Market Cap 2011-2026 | ADMP
As of April 29, 2026 Adamis Pharmaceuticals Corporation has a market cap of $ 117 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 M | 86.5 M | 61.3 M | 35.7 M | 121 M | 103 M | 54.3 M | 63.1 M | 39.8 M | 49.8 M | 58.2 M | 14.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 121 M | 14.7 M | 58.8 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | ||
|
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | ||
|
Cronos Group
CRON
|
3.63 B | $ 2.59 | -2.26 % | $ 1.32 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 4.21 | -1.64 % | $ 59.2 M | ||
|
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | ||
|
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | ||
|
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | ||
|
Bausch Health Companies
BHC
|
3.38 B | $ 5.62 | -1.06 % | $ 2.05 B | ||
|
Organogenesis Holdings
ORGO
|
415 M | $ 2.33 | -2.92 % | $ 307 M | ||
|
Pacira BioSciences
PCRX
|
1.18 B | $ 25.14 | -1.06 % | $ 1.16 B | ||
|
Canopy Growth Corporation
CGC
|
142 M | $ 1.1 | -4.35 % | $ 118 M | ||
|
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | ||
|
Harrow Health
HROW
|
1.93 B | $ 39.29 | -2.94 % | $ 1.44 B | ||
|
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 1.1 | 5.77 % | $ 1.37 M | ||
|
Tilray
TLRY
|
1.19 B | $ 6.07 | -7.43 % | $ 3.75 B | ||
|
OrganiGram Holdings
OGI
|
382 M | $ 1.39 | -1.07 % | $ 402 M | ||
|
Veru
VERU
|
108 M | $ 2.24 | -2.18 % | $ 302 M | ||
|
Viatris
VTRS
|
18.4 B | $ 15.0 | 1.21 % | $ 18 B | ||
|
Evolus
EOLS
|
271 M | $ 5.19 | -1.52 % | $ 335 M | ||
|
Sundial Growers
SNDL
|
889 K | $ 1.34 | -8.84 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
139 M | $ 8.11 | -1.52 % | $ 415 M | ||
|
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | ||
|
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | ||
|
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | ||
|
cbdMD
YCBD
|
1.68 M | $ 0.79 | -14.27 % | $ 3.41 M | ||
|
Assertio Holdings
ASRT
|
75.4 M | $ 18.08 | 0.22 % | $ 116 M | ||
|
Solid Biosciences
SLDB
|
623 M | $ 7.16 | -3.89 % | $ 627 M | ||
|
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
247 M | $ 7.29 | 0.69 % | $ 288 M | ||
|
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
37.9 M | $ 0.96 | -2.51 % | $ 47.9 M | ||
|
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | ||
|
Aurora Cannabis
ACB
|
915 M | $ 3.29 | -3.8 % | $ 86.3 M | ||
|
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
33.8 M | $ 0.88 | -0.57 % | $ 31.7 M | ||
|
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
2.75 M | $ 0.52 | -6.68 % | $ 2.23 M | ||
|
TherapeuticsMD
TXMD
|
23 M | $ 2.12 | 0.71 % | $ 24.5 M |